Advances in computational methods for PROTAC drug discovery
Massyel S Martinez-Cortés1, Carlos A Velázquez-Martínez2, José L Medina-Franco1
1DIFACQUIM Research Group, Department of Pharmacy, School of Chemistry, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
Abstract:
Proteolysis-targeting chimeras (PROTACs) represent a transformative strategy in drug discovery, enabling the selective degradation of target proteins rather than merely inhibiting their activity. However, their structural complexity and deviation from conventional drug-like properties present major challenges for traditional design and optimization methods. In this review, we provide a comprehensive overview of recent computational advances that facilitate PROTAC development, encompassing chemoinformatics, structural bioinformatics, molecular modeling and machine learning resources. We highlight computational tools for warhead and linker design, ternary complex modeling and the prediction of degradation efficiency and ADMET profiles. Finally, we discuss current limitations and future perspectives, emphasizing strategies to enhance design effectiveness and accelerate clinical translation.
Related Concept Videos
Protein-protein Interfaces
Drug Discovery: Overview
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Protein-Drug Binding: Determination Methods
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
Pharmacogenomics: Identification of New Drug Targets


